Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-Part, Phase 2, Open-Label, Randomized, Fixed Sequence Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Epinephrine After Single and Repeat Doses of DESF in Healthy Adults with Oral Allergy Syndrome (OASIS: Oral Anaphylm Symptom Intervention Study)

Next Previous
Trial Profile

A 2-Part, Phase 2, Open-Label, Randomized, Fixed Sequence Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Epinephrine After Single and Repeat Doses of DESF in Healthy Adults with Oral Allergy Syndrome (OASIS: Oral Anaphylm Symptom Intervention Study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AQST 109 (Primary) ; AQST 109 (Primary)
  • Indications Anaphylaxis
  • Focus Pharmacokinetics
  • Acronyms OASIS; Oral Allergy Syndrome (OAS) challenge study
  • Sponsors Aquestive Therapeutics

Most Recent Events

  • 25 Jun 2025 According to an Aquestive Therapeutics media release, the company announced that the poster presentation highlighting results from the study will be presented at the Center for Food Allergy and Asthma Research (CFAAR) Food Allergy Summit , which will be held June 27-29 in Chicago, Ill.
  • 25 Jun 2025 According to an Aquestive Therapeutics media release, the company announced that the poster presentation highlighting results from the study was originally presented at the 2025 AAAAI Annual Meeting.
  • 12 Feb 2025 According to Aquestive Therapeutics media release, data from this study will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting. The meeting will take place February 28 - March 3, 2025, in San Diego, CA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top